Allergan Seeks Opportunities To Dominate In Key Therapeutic Areas
This article was originally published in Scrip
Allergan plc is known as one of the most acquisitive players in the pharmaceutical industry, but the company asserted its commitment to in-house and early-stage innovation as well during R&D Day presentations on Nov. 4, reflecting a strategy similar to its potential acquirer Pfizer Inc.
You may also be interested in...
Allergan PLC will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva Pharmaceutical Industries Ltd. to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its dealmaking net.
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.